





UoL Spinouts summary for LSX Investival Showcase EU event


APØELLO			Website: Apoello	
Technology	Unique SaaS platform transforms months of trial-and-error research into precision-guided discovery. Instantly reveal high-performance materials for organic electronics, solar energy, laser dyes, photocatalysis, imaging diagnostics, phototherapies and more.			
Vision	Apoello Ltd is a UK-based deep tech company focused on transforming molecular discovery through digitisation and automation. Building on research from leading academic groups, we combine chemical data, computational tools, and practical materials access in our flagship DiaDEM™ platform. We believe the future of molecular and materials discovery is digital. By bridging the gap between computation and experimentation, Apoello empowers researchers to move faster, reduce trial-and-error, and focus on solving real-world challenges across optoelectronics, sensors, energy, and healthcare.			
Sector	Organic Material Discovery	CEO & Founders	Omer Omar, Co-Founder & CEO Prof Alessandro Troisi, Co-Founder and Head of STAB	
Total Investment Received	£50k £50k UoL EIF (UoL EIF £100k Tranche on full funding round)	Funding Round	SEIS or EIS Available	Next funding round target
		Seed	SEIS & EIS	Pre-Seed £250k Q4 2025 Seed £1.5M Q1 2027


			Website: SenseAI	
Technology	Powering disruptive imaging technologies through integrated AI; software company in compressive sensing and deep learning for self-driving acquisition optimization, feature recognition and analysis while significantly reducing data transfer and storage.			
Vision	Solutions that unlock computational imaging across a range of EM applications in semiconductors, life sciences and material science sectors			
Sector	Digital	CEO & Founders	Dan Somers, CEO Prof Nigel Browning, CSO	
Total Investment Received	Total £1.51M investment £200K UoL EIF £700K Foresight £710K syndicate (AXM, LYVA Labs, Sivananthan Laboratories, Wren Capital, Haatch)	Funding Round	SEIS or EIS Available	Next funding round target
		Seed	EIS available	Series A Q1 2027


				Website: TandemNano
Technology	Chemical Reformulation/Long Acting Therapeutics			
Vision	Tandem Nano Ltd (TNL) simplifies therapeutic dosing. Through oral and long-acting nanoformulations we reduce the cost and frequency of dosing to transform drug therapy and facilitate equal, global access to medication.			
Sector	Manufacturing (Chemicals), Agrotech, Pharma	CEO & Founders	Antony Odell, CEO Prof Andrew Owen, CSO Prof Steve Rannard, CTO	
Total Investment Received	Total £700K	Funding Round	SEIS or EIS Available	Next funding round target
	£200K NG Studios £500K UoL EIF	Seed	SEIS & EIS available	£1.5m – Q1 2026


			Website: Sulantrix	
Technology	Novel targets pseudokinases for cancer therapy			
Vision	Sulantrix is a UK-based Biotech company focused on modulating ‘zombie’ proteins belonging to the pseudokinase target class with new small molecule drugs to treat disease. Our mission is to create medicines which provide a real benefit to patients suffering from diseases where treatment options aren’t available or where existing medicines have stopped working.			
Sector	Drug Development	CEO & Founders	David Williams, CEO Prof Patrick Eyers, CSO	
Total Investment Received	£300K	Funding Round	SEIS or EIS Available	Next funding round target
	£300K UoL EIF	Pre-Seed	SEIS & EIS available	Seed of up to £8m 2026 Series A of £25m

 <div>ALL YOUR EYE NEEDS</div>			Website: Ocuwell	
Technology	Portable device for topographic corneal maps. enabling diagnosis and disease staging for keratoconus and other conditions			
Vision	At OCUWELL, we’re breaking down these barriers by transforming corneal diagnostics and treatment strategies – because every person deserves access to sight-saving technology.			
Sector	Diagnostics	CEO & Founders	Rania Maklad, CEO Prof Ahmed Elsheikh, CSO	
Total Investment Received	Total £865K	Funding Round	SEIS or EIS Available	Next funding round target
	£250K Deepbridge Capital £250K LYVA Labs £200K NG Studios £165K UoL EIF >£2m non-equity grants (UKRI IUK, NIHR, Royal Society)	Seed	EIS available	Series A – £3M Q2 2026

				Website: Innovtive Dx	
Technology	Easy to use, cheaper point of care diagnostic kits for faster and more accurate diagnosis and accurate antibiotic prescription for urinary tract infections				
Vision	We're working towards a future where everyone has equal access to excellent, fast diagnostics. Our scalable system paves the way towards global antimicrobial stewardship.				
Sector	Diagnostics	CEO & Founders	Will Wijnberg, CEO Dr Srijan Jindal, CSO and co-founder		
Total Investment Received	£8M+ received in multiple closes from HNWI	Funding Round	SEIS or EIS Available	Next funding round target	
		Seed	EIS £5M (remaining) No SEIS	Seed £10m Q2 - 2026	

 ReNewVax Ltd.			Website: ReNewVax	
Technology	Vaccines to prevent life-threatening bacterial infections and combat AMR			
Vision	ReNewVax is a next-generation bacterial vaccine company developing the first universal vaccine targeting all ca.100 existing variants of S. pneumoniae, or pneumococcal, bacteria.			
Sector	Vaccines	CEO & Founders	Neil Murray, CEO Dr Miguel Leon-Rios, Head of Research	
Total Investment Received	Total £990K	Funding Round	SEIS or EIS Available	Next funding round target
	UoL EIF £250K SEIS (SFC)	Seed	No SEIS	£4m additional non-dilutive philanthropic fund
	LYVA Labs £250K		EIS available	Series A £15M Q1 2026

			Website: AI Sight	
Technology	Deploying novel AI to reduce vision loss for people with diabetes			
Vision	AI-Sight can provide WHO recommended diabetic eye screening services across the globe. It is a highly sensitive and specific, low-cost, web-based diagnostic tool capable of image interpretation across diabetic retinopathy (DR) disease severity and treatment intervention points worldwide.			
Sector	Diagnostics	CEO & Founders	Dr Steven Powell, CEO Prof Simon Harding MBE, CMO	
Total Investment Received	TOTAL £1,525M Pre-seed £1m closed from HNWI	Funding Round	SEIS or EIS Available	Next funding round target
		Seed	No SEIS EIS remaining £9.5m	Seed Plus – Q3 2026 £4M

			Website: TrophCell Ltd	
Technology	Making cell therapy reliable, affordable and effective first-time treatment for major disease classes			
Vision	The TrophiCell Vision is to develop and deliver the safest and most clinically effective cell therapeutics to patients.			
Sector	Therapeutics	CEO & Founders	Dr Karen Sullivan, CEO Prof Anthony Hollander, Founder and CSO	
Total Investment Received	£50K	Funding Round	SEIS or EIS Available	Next funding round target
	£50K UoL EIF	Seed	Straight to Series A raise to £5m, not pursuing SEIS/EIS	Series A raise to £5m, (pharma / CDMO)



Website: [GalyTx](http://GalyTx.com)

Technology	First in class non-carbohydrate small molecule Galectin3 inhibitors, with excellent anti-cancer in vivo data and promising drug characteristics.			
Vision	Galytx aims to deliver maximum clinical value from galectin-3 targeted therapies. Our pipeline of assets will enable us to deliver therapeutics for indications requiring either/both chronic and/or acute administration where necessary. This strategy will enable us to provide effective therapies for the broadest range of galectin-3 mediated diseases.			
Sector	Drug Development	CEO & Founders	Dr Karen Sullivan, Co-Founder and CEO; Prof Lu—Gang Yu, Co-Founder and CSO,	
Total Investment Received	£112K	Funding Round	SEIS or EIS Available	Next funding round target
	£112K UoL EIF	Pre-Seed	EIS available	Series A - £18m (Max) To fund clinical trials